SAN CARLOS, Calif., March 08, 2021 (GLOBE NEWSWIRE) — Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases and a subsidiary of Grifols, today announced it will be delivering a presentation of data from a completed study of its therapeutic plasma fraction candidate, GRF6021, in subjects with Parkinson’s disease (PD) and cognitive impairment at the virtual 15th International Conference on Alzheimer’s and Parkinson’s Diseases. Presentation and discussion session details are included below.
Presentation Details:
Title: A Randomized, Double-blind, Placebo-controlled Trial Assessing The Safety And Tolerability Of GRF6021 In Subjects With Parkinson’s Disease And Cognitive Impairment
Presenter: Esther Rawner, M.D., Senior Medical Director
Date: Wednesday, March 10, 2021
Time: 14:00 – 14:15 CET
Session: Translational Treatment Strategies 1
Conference Registration and Access Link: https://adpd.kenes.com/register/
Discussion Session Details:
Date: Wednesday, March 10, 2021
Time: 17:00 – 17:30 CET
Alkahest is studying GRF6021 as a potential treatment for age-related diseases in collaboration with clinical development partner and parent company, Grifols. GRF6021 is a proprietary plasma fraction that has enhanced neurogenesis, improved age-related deficits in learning and memory and reduced neuroinflammation in preclinical animal models.
In the phase 2 clinical study of GRF6021 in subjects with PD and cognitive impairment, GRF6021 demonstrated positive effects on cognitive endpoints and was safe and well tolerated by study participants. Alkahest plans to further study efficacy of GRF6021 in patients to advance its clinical development.
About Grifols
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 countries.
Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat chronic, rare and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.
Grifols, with nearly 24,000 employees in 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.
In 2020, Grifols’ economic impact in its core countries of operation was EUR 7.5 billion. The company also generated 140,000 jobs, including indirect and induced.
The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).
Alkahest is a clinical stage biopharmaceutical company dedicated to discovering and developing treatments for neurodegenerative and age-related diseases with transformative therapies targeting the aging plasma proteome. The Alkahest pipeline includes multiple therapeutic candidates ranging from selected plasma fractions to protein-targeted interventions which aim to slow the detrimental biological processes of aging.
For more information, please visit www.grifols.com or www.alkahest.com.
Media Contact
Michael Tattory
LifeSci Communications
1 (646) 751-4362
mtattory@lifescicomms.com
Grifols Media Press Office
media@grifols.com
Tel. +34 571 00 02
LEGAL DISCLAIMER
The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.